Circulating Tumor DNA Monitoring in Patients with Uveal Melanoma Using Mutation-Agnostic Multiplex Drop-Off ddPCR Assays
A simpler blood test for uveal melanoma detects tumor DNA without requiring prior genetic testing, making real-time treatment monitoring more accessible.
Novel mutation-agnostic multiplex drop-off ddPCR assays covering 6 hotspot mutations in GNAQ, GNA11, SF3B1, PLCB4, and CYSLTR2 achieve 0.06–0.13% detection limits for ctDNA monitoring in metastatic uveal melanoma without requiring prior tumor NGS genotyping. ctDNA was detected in 62.8% of prospective plasma samples with concordance r=0.97–0.98 against simplex ddPCR, offering a more accessible and cost-effective real-time treatment monitoring strategy for this rare and aggressive cancer.
What the study was
- Study design
- Prospective cohort validation of a novel analytical assay
- Population
- Patients with metastatic uveal melanoma (prospective cohort, ALCINA study NCT02866149)
- Sample size
- 43
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Analytical Chemistry
Why it surfaced
Mutation-agnostic approach to ctDNA monitoring in uveal melanoma eliminates the NGS pre-requirement while maintaining high analytical sensitivity; clinically validated in prospective ALCINA cohort. Rare cancer (uveal melanoma) with high unmet need for sensitive liquid biopsy monitoring tools. Institut Curie provenance adds credibility.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.